Loading
Everything OnCo dates to 2025: 610 entries, 129 trials reported, 126 papers, 90 landmarks and 78 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
610 dated entries in OnCo fall in 2025: 129 trials reported, 126 papers, 90 landmarks, 78 approvals, 68 regulatory events, 58 papers listed on people's pages, 34 financing rounds, 12 technologies, 8 guideline changes, 5 expected dates, 1 company founded and 1 law or regulation.
Of those, 30 to the day, 46 to the month, 1 to the quarter and 533 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Localised prostate cancer risk stratification and ADT benefit prediction
Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK...
KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)
R/R myeloma with BorDex or PomDex; 23 Jul 2025
Relapsed/refractory myeloma after ≥1 prior line, in combination
ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional). Conditional marketing authorisation
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
Intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic therapy (Korjuny)
Adjuvant high-risk CSCC after surgery and radiation
mHSPC with ADT alone (ARANOTE)
HR+/HER2- mBC after endocrine + chemo; 4 Apr 2025
HR-positive, HER2-negative unresectable or metastatic breast cancer after endocrine therapy and at least one line of chemotherapy; marketing authorisation issued 4 April 2025.
HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy
EGFR-mutant NSCLC after EGFR TKI and platinum chemotherapy
Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)
Adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no other suitable donor cells
Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin.
Resectable non-small-cell lung cancer (4 cm or more, or node positive) without an EGFR mutation or ALK rearrangement, neoadjuvant with platinum chemotherapy then adjuvant alone.
Limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy.
Metastatic colorectal cancer at third line or later, only when trifluridine-tipiracil with bevacizumab is unsuitable.
BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumours
PATHWAY 4B5 extended to HER2-ultralow (IHC 0 with membrane staining)
Gozellix kit; selection of patients for PSMA-targeted radioligand therapy
Lower-risk MDS transfusion-dependent anaemia
ER+/HER2- ESR1-mutated advanced breast cancer after ≥1 line of endocrine therapy
PIK3CA-mutant ER+/HER2- mBC with palbociclib + fulvestrant; 18 Jul 2025
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab. TA1065, published 28 May 2025.
1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025
R/R myeloma ≥3 lines; 23 Apr 2025 (conditional). Conditional marketing authorisation
Relapsed/refractory myeloma after ≥4 lines (accelerated)
ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor.
First-line maintenance with atezolizumab in ES-SCLC (full approval)
PSMA+ mCRPC after ARPI, before chemotherapy
Symptomatic, inoperable plexiform neurofibromas in NF1, age 2 and over (Ezmekly, conditional)
NF1 with symptomatic plexiform neurofibromas not amenable to complete resection, adults and children 2 and over (Gomekli)
Recurrent low-grade intermediate-risk NMIBC (intravesical gel)
First-line treatment of metastatic adenocarcinoma of the pancreas (Onivyde pegylated liposomal with oxaliplatin, fluorouracil and leucovorin), listed in the EMA therapeutic indicat...
Progressing desmoid tumours
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab. TA1065, published 28 May 2025, within the marketing authorisation and subject to the comme...
Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab. Approved 8 April 2025 on CheckMate 8HW.
Relapsed or refractory B-ALL, adults ≥26 years
R/R follicular lymphoma after ≥2 lines (accelerated)
BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial a...
Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection.
Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy.
Acromegaly in adults
KRAS G12C mCRC with sotorasib
Adjuvant treatment of non-small-cell lung cancer at high risk of recurrence after complete resection and platinum chemotherapy.
Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line
Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)
ROS1+ NSCLC; NTRK+ solid tumours; 13 Jan 2025 (conditional). Conditional marketing authorisation
Locally recurrent or metastatic anal SCC with carboplatin-paclitaxel; monotherapy after platinum
Relapsed/refractory NPM1-mutant AML
CLDN18.2+ advanced gastric/GEJ adenocarcinoma, previously treated
With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)
Previously treated RET fusion-positive advanced non-small-cell lung cancer not previously treated with a RET inhibitor.
First-line ES-SCLC with carboplatin-etoposide
HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy (accelerated)
Relapsed/refractory MCL and CLL/SLL after BTK inhibitor
KRAS G12C colorectal cancer with panitumumab
KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with panitumumab. Approved 16 January 2025 on CodeBreaK 300.
Locally advanced/metastatic NSCLC with EGFR exon 20 insertions after platinum
R/R follicular lymphoma with lenalidomide and rituximab
ROS1-positive NSCLC
Locally advanced or metastatic ROS1-positive NSCLC
Extensive-stage small-cell lung cancer progressing after two or more lines of treatment including platinum-based chemotherapy: not recommended.
c-MET-high non-squamous NSCLC, previously treated (accelerated)
First-line ESCC, PD-L1 ≥1%, with platinum chemotherapy
Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025
HER2-low/ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)
HER2-mutant NSCLC after ≥1 systemic therapy (May 2025)
Preparative regimen for allogeneic HSCT in AML/MDS with fludarabine
Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025
Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity
Grade 2 IDH-mutant glioma ≥12 yrs; 17 Sep 2025
HER2+ biliary tract after ≥1 line; 27 Jun 2025 (conditional). Conditional marketing authorisation
Relapsed/refractory NPM1-mutated AML with no satisfactory alternative
HER2-mutant NSCLC, previously treated (accelerated)
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
MAA submitted to EMA, UK, Australia, Switzerland
European Commission approval
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum
MHRA approval
With sotorasib for KRAS G12C mCRC (CodeBreaK 300)
KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)
HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy (TROPION-Breast01)
HER2-low and HER2-ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)
European Commission approval for ES-SCLC
Phase 3 vs T-DM1 in residual disease registered (NCT06830889)
MOTION
COMPETE topline at ENETS 2025
IND cleared; first-in-human phase 1 started
Second CRL
Second complete response letter
First approval worldwide for HR+/HER2- breast cancer (December 2024, Japan MHLW)
EGFR-mutant NSCLC after TKI failure
First-line ESCC PD-L1 ≥1% (RATIONALE-306)
NET indication on CABINET
Perioperative muscle-invasive bladder cancer (NIAGARA)
PSMA+ mCRPC after ARPI, before chemotherapy (PSMAfore)
With nivolumab first-line MSI-H/dMMR colorectal cancer (CheckMate 8HW)
First-line PD-L1+ NSCLC (HARMONi-2)
Pheochromocytoma/paraganglioma
Breakthrough Therapy designation, PIK3CA-wild-type HR+/HER2- breast cancer after CDK4/6
BLA withdrawn after HERTHENA-Lung02 met PFS but not OS
HER2-mutant NSCLC
Accelerated approval on RAMP 201; RAMP 301 confirmatory
Accelerated approval, previously treated c-MET-high non-squamous NSCLC (LUMINOSITY)
CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome
Full approval in NSCLC (KRYSTAL-12)
REMS requirements removed for CAR-T class
Breakthrough Therapy designation, dMMR locally advanced rectal cancer (organ preservation)
OS benefit added to label
Conditional marketing authorisation
NDA submitted (ROSELLA)
Breakthrough Device designation for Shield multi-cancer (MCD)
Phase 3 DeLLphi-304 OS benefit presented; conversion to full approval pursued
NDA submitted (VERITAC-2)
EMA approval
NDA based on SERENA-6
EGFR-mutant NSCLC after TKI and platinum chemotherapy (accelerated)
REMS requirements removed for approved CAR-T products
Complete response letter for STARGLO combination (regional heterogeneity); approved in EU
Accelerated approval (LINKER-MM1)
Complete response letter citing trial design and heterogeneity
Complete response letter on combination filing; resubmitted
Accelerated approval in follicular lymphoma
US rights sold by Adaptimmune to US WorldMeds
Asset transferred to US WorldMeds; BLA committed by end-2026
Accelerated approval, previously treated HER2-mutant non-squamous NSCLC (Beamion LUNG-1)
De novo authorisation: first AI pathology test cleared for prognostic and predictive use in localised prostate cancer
Subcutaneous formulation (PALOMA-3)
Subcutaneous pembrolizumab (Keytruda Qlex)
First CAR-T approved for a solid tumour (CLDN18.2+ gastric/GEJ adenocarcinoma)
FDA approval of Inlexzo
Approved as Inluriyo
Approval in combination regimens for relapsed/refractory myeloma after ≥1 line (DREAMM-7/8)
Adjuvant high-risk CSCC after surgery and radiation (C-POST)
Relapsed/refractory NPM1-mutant AML
Full approval with atezolizumab as first-line maintenance (IMforte)
Perioperative gastric/GEJ cancer with FLOT (MATTERHORN)
KOMET-001; priority review
First-line urothelial cancer with toripalimab, positive phase 3
Full approval based on DeLLphi-304
First-line HER2+ gastro-oesophageal adenocarcinoma (HERIZON-GEA-01) submission
Traditional approval; label broadened to any prior covalent BTKi
Muscle-invasive bladder cancer (EV-303/304) submissions following positive results
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row recategorised. Anchored to FDA approval of 177Lu-PSMA-617 before taxane chemotherapy, March 2025 (PSMAfore).
2 rows added, 1 row recategorised. Anchored to FDA approvals of adagrasib with cetuximab (June 2024), encorafenib with cetuximab and mFOLFOX6 in the first line (December 2024, BREA...
1 row added, 1 row removed. Anchored to FDA approval of datopotamab deruxtecan for EGFR-mutant NSCLC after TKI and chemotherapy (June 2025, TROPION-Lung05); withdrawal of the patri...
1 row added. Anchored to FDA approval of trastuzumab deruxtecan with pertuzumab in the first line, 2025 (DESTINY-Breast09).
2 rows added. Anchored to FDA approvals of perioperative durvalumab with gemcitabine-cisplatin (March 2025, NIAGARA) and the TAR-200 intravesical gemcitabine system for BCG-unrespo...
1 row recategorised, 1 row added. Anchored to FDA approvals of trastuzumab deruxtecan for HER2-low or ultralow disease after endocrine therapy (January 2025, DESTINY-Breast06) and...
1 row added. Anchored to FDA re-approval of belantamab mafodotin in combination, October 2025 (DREAMM-7, DREAMM-8), after the 2022 withdrawal.
2 rows added. Anchored to FDA approvals of revumenib for KMT2A-rearranged acute leukaemia (November 2024, AUGMENT-101) and ziftomenib for NPM1-mutated AML (2025, KOMET-001).
The year reported on trial records, with the headline result the record gives.
Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.1 months; median progres...
Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.
3-year recurrence HR 0.49 (PIK3CA hotspot) and 0.42 (other PI3K alterations).
iDFS HR 1.11 (0.87 to 1.42), p 0.38; stopped for futility at 2,199 of 2,300 patients.
ORR 31% in heavily pretreated ALK+ NSCLC; NDA under priority review.
ORR 54.3% (PRRT-naive); all primary endpoints met.
PFS HR 0.62.
PFS HR 0.65; PFS2 improved.
3-year DFS 86.4% vs 76.6%, HR 0.50.
Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.
OS 30.3 vs 15.1 months (HR 0.49); PFS 12.8 vs 7.1 months.
Weight loss achieved; primary iDFS endpoint not met at first analysis (presented 2025; publication pending, verify).
Disease-free survival at 24 months 87.1 per cent with adjuvant cemiplimab against 64.1 per cent with placebo (hazard ratio 0.32, 95 per cent confidence interval 0.20 to 0.51, p<0.0...
Median rPFS 33.2 against 25.7 months, HR 0.81 (95% CI 0.66 to 0.98, p=0.034); OS HR 0.90 at 26.4% maturity; approved 2026.
DFS HR 0.72; OS HR 0.63; 8-year OS 90.3% vs 83.2%.
PFS 23.9 vs 14.1 months, HR 0.67.
Overall R0 resection rate 25 percent with chemoradiotherapy against 18 percent with chemotherapy (p 0.113); R0 among operated patients 69.4 against 50.0 percent (p 0.04); overall s...
Median progression-free survival 3.25 vs 1.77 months (hazard ratio 0.37) in 156 randomised patients.
OS HR 0.60.
3-year iDFS 92.4% vs 83.7%, HR 0.47.
PFS HR 0.56.
pCR 67.3% vs 56.3%.
OS 14.7 vs 11.4 months, HR 0.70.
ctDNA is strongly prognostic (three-year recurrence-free survival 87 against 49 percent) but de-escalation was not non-inferior and escalation did not help.
rPFS significantly improved.
EFS HR 0.40; OS HR 0.50; pCR 57.1% vs 8.6%.
EFS, OS, and pCR significantly improved (topline; details pending).
PFS HR 0.56 (ITT); HR 0.38 (ESR1-mutant).
Interim OS 17.9 vs 12.5 months (HR 0.61); benefit attenuated on follow-up.
PFS HR 0.75; 2-year PFS 71.1% vs 62.9%.
PFS 24.9 vs 16.3 months, HR 0.64.
PFS HR 0.77 (5.8 vs 5.4 months); OS not significant; BLA withdrawn.
PFS 30.6 vs 8.3 months, HR 0.22.
OS 13.2 vs 10.6 months (HR 0.73); PFS HR 0.54.
ORR 97%.
DFS HR 0.64; OS HR 0.59 in ctDNA+.
Five-year invasive disease-free survival 91.9 percent without axillary surgery against 91.7 percent with sentinel node biopsy (hazard ratio 0.91, 0.73 to 1.14, non-inferior); axill...
5-year recurrence-free ~98% (no RAI) vs ~96% (RAI).
Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months...
Median EFS 59.7 vs 29.6 months (CPS ≥1).
Median radiographic progression-free survival 8.6 against 8.3 months (hazard ratio 0.85, 95 percent confidence interval 0.71 to 1.01) and overall survival 19.6 against 19.0 months...
Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility.
OS 18.2 vs 14.0 months in CPS ≥1 (HR 0.76); ITT OS HR 0.82.
CR 23%, ORR 33%, median OS 6.6 months.
iDFS ~30% relative reduction (HR ~0.70).
36-month PFS 83.4% vs 29.7%; HR ~0.17.
EFS HR 0.71; OS HR 0.78; 3-year OS 68.6%.
Three-year disease-free survival 63.1% vs 52.5% (hazard ratio 0.76).
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
Regional nodal irradiation after a complete nodal response to chemotherapy did not lengthen the invasive breast cancer recurrence-free interval (hazard ratio 0.88, 0.60 to 1.28, p=...
OS 16.2 vs 14.2 months, HR 0.82.
Post hoc analyses in 17 participants suggested that patidegib topical gel reduced the number of new surgically eligible basal cell carcinomas and the level of hedgehog signalling...
Objective response in 54.5 per cent (95 per cent confidence interval 44.2 to 64.4) with complete responses in 17.8 per cent, median progression-free survival 16.0 months, and 63 pe...
Median progression-free survival 9.3 months with retifanlimab plus carboplatin-paclitaxel against 7.4 months with placebo (hazard ratio 0.63, one-sided p 0.0006); approved in the U...
DFS HR 0.68.
Implant loss 8.2 percent at three months and a complication in 42.0 percent; physical and sexual wellbeing fell significantly against baseline at three and eighteen months, and two...
Sensitivity 79.2% for colorectal cancer and specificity 91.5% for advanced colorectal neoplasia (n = 27,010 evaluable); all primary endpoints met; advanced precancerous lesion sens...
Median overall survival 21.9 months with neoadjuvant FOLFIRINOX against 21.3 months with neoadjuvant gemcitabine chemoradiotherapy and adjuvant gemcitabine (hazard ratio 0.88, 95 p...
rPFS HR 0.72 (95% CI 0.58 to 0.90, p=0.0021), medians not reached in either arm at the second interim analysis; overall survival not yet reported.
ORR 55.6% (ovarian, 120 mg/m²); 50% (endometrial, 100 mg/m²).
RFS not improved.
Severe oral mucositis incidence 54% vs 64% (relative risk 0.84, 95% CI 0.71 to 1.00; p = 0.045); median duration 8 vs 18 days (p = 0.002).
OS 16.0 vs 11.9 months (HR 0.69).
Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent...
PFS 16.0 vs 9.2 months, HR 0.44.
ORR ~64%; accelerated approval Nov 2025.
261 lung cancers in 12,773 participants, 79.3 percent at stage 1 or 2; episode sensitivity 97.0 percent and false-positive rate 4.8 percent; uptake 1.89 times higher in the least d...
PFS improved (HR reported 2025).
Ten-year overall survival 81.4 percent with chest-wall irradiation against 81.9 percent without (hazard ratio 1.04, p=0.80); chest-wall recurrence 1.1 against 2.5 percent (hazard r...
OS 14.0 vs 13.6 months, HR 0.91 (0.72 to 1.14), p=0.41; PFS 7.5 vs 6.3 months, HR 0.89; gallbladder PFS interaction p=0.01, OS interaction p=0.28.
Median progression-free survival 31.9 months with ibrutinib plus venetoclax against 22.1 months with ibrutinib plus placebo (hazard ratio 0.629, p 0.0024); complete response 69.2 p...
ORR 73% (37 of 51) in relapsed or refractory B-cell malignancies; two treatment-related deaths.
OS 23.7 vs 18.7 months; PFS also improved.
Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.
PFS HR 0.57 in ESR1-mutant; ITT not significant.
Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.
PLCOm2012 at 1.51 percent detected 91.1 percent of cancers against 62.8 percent for the 2013 USPSTF rule; incremental cost-effectiveness 3,797 to 4,013 pounds per quality-adjusted...
The publication year on key paper records.
Hughes BGM, Guminski A, Bowyer S, et al. Journal of the American Academy of Dermatology.
Xiang J, Wang X, Zhang X, et al. Nature.
Smith M, Piulats J, Todenhöfer T, et al. The Lancet Oncology.
Halder P, Dixit J, Gupta N, et al. The Lancet regional health. Southeast Asia.
Hwang ES, Hyslop T, Lynch T, et al. JAMA.
Long GV, Garnett-Benson C, Dolfi S, et al. Nature Medicine.
Brown JR, Seymour JF, Jurczak W, et al. New England Journal of Medicine.
Dimopoulos MA, Voorhees PM, Schjesvold F, et al. New England Journal of Medicine.
Anderson C, Lee CM, Kelley JR, et al. eClinicalMedicine.
Heymach JV, Ruiter G, Ahn MJ, et al. New England Journal of Medicine.
Benson AB, D'Angelica MI, Abrams T, et al. Journal of the National Comprehensive Cancer Network.
Wang J, Zhang Q, Li H, et al. Nature Communications.
Elez E, Yoshino T, Shen L, et al. New England Journal of Medicine.
Rischin D, Porceddu S, Day F, et al. New England Journal of Medicine.
Chan JA, Geyer S, Zemla T, et al. New England Journal of Medicine.
Agarwal N, Azad AA, Carles J, et al. The Lancet Oncology.
Usmani SZ, Facon T, Hungria V, et al. Nature Medicine.
Courneya KS, Vardy JL, O'Callaghan CJ, et al. (Canadian Cancer Trials Group CO.21). New England Journal of Medicine.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. New England Journal of Medicine.
André T, Elez E, Lenz HJ, et al. The Lancet.
Gupta S, Rau RE, Kairalla JA, et al. New England Journal of Medicine.
Tie J, Wang Y, Lo SN, et al. Nature Medicine.
Qi C, Liu C, Peng Z, et al. The Lancet.
Shaukat A, Burke CA, Chan AT, et al. JAMA.
Langerbeins P, Robrecht S, Nieper P, et al. Journal of Clinical Oncology.
Peled N, Tufman A, Sequist LV, et al. ESMO Open.
Sands J, Ahn MJ, Lisberg A, et al. Journal of Clinical Oncology.
Yu J, He AR, Ouf M, et al. JCO Precision Oncology.
Laktionov K, Smolin A, Stroyakovskiy D, et al. European Journal of Cancer.
Hsiehchen D, Kainthla R, Kline H, et al. Nature Communications.
Oh DY, He AR, Qin S, et al. Journal of Hepatology.
Lu S, Wu L, Wang Q, et al. Journal of Thoracic Oncology.
Chen D, Le SB, Ghiaseddin AP, et al. Med (New York, N.Y.).
Paz-Ares L, Borghaei H, Liu SV, et al. The Lancet.
Shi Y, Wu L, Ji Y, et al. The Lancet. Respiratory medicine.
Cardoso F, Parke S, Brennan DJ, et al. New England Journal of Medicine.
Sangro B, Kudo M, Erinjeri JP, et al. The Lancet.
Kopetz S, Yoshino T, Van Cutsem E, et al. Nature Medicine.
Cho BC, Li W, Spira AI, et al. Journal of Thoracic Oncology.
Schram AM, Goto K, Kim DW, et al. New England Journal of Medicine.
Brody JD, Jørgensen J, Belada D, et al. Blood.
Darman L, Kaurich Q, Hassan MS, et al. International journal of molecular sciences.
Li Q, Vignali P, Tang D, et al. Cancers.
Jänne PA, Goto Y, Kubo T, et al. Journal of Thoracic Oncology.
Kummar S, Razak AA, Laurie S, et al. Cancer research communications.
Baldini C, Verlingue L, Goldschmidt V, et al. Journal of Clinical Oncology.
Bidard FC, Mayer EL, Park YH, et al. New England Journal of Medicine.
Jänne PA, Wang BC, Cho BC, et al. Journal of Clinical Oncology.
Hong S, Wang Q, Cheng Y, et al. Nature Medicine.
Ruan DY, Wu HX, Xu Y, et al. Signal transduction and targeted therapy.
Suryavanshi M, Ostwal V, Javle MM, et al. JCO Global Oncology.
Díaz-Gay M, Dos Santos W, Moody S, et al. Nature.
Shi Y, Fang J, Xing L, et al. Nature Medicine.
Zhou C, Chen J, Wu L, et al. The Lancet.
Patkar S, Shah TM, Varty G, et al. Cancer Epidemiology.
Zhan J, Xue J, Wu L, et al. Journal of translational medicine.
Wong MK, Milhem MM, Sacco JJ, et al. Journal of Clinical Oncology.
Jhaveri KL, Neven P, Casalnuovo ML, et al. New England Journal of Medicine.
Demidov L, Samoylenko I, Kharkevich G, et al. European Journal of Cancer.
Powles T, Chang Y-H, Yamamoto Y, et al. New England Journal of Medicine.
Mujumdar V, Huang M, Smith LC, Musa F. Gynecologic Oncology Reports.
Patel Y, Chawla J, Parmar MS. Current Oncology Reports.
Straughn JM. Gynecologic Oncology Reports.
Chen Z, Yang F, Jiang Z, et al. The Lancet.
Uppaluri R, Haddad RI, Tao Y, et al. New England Journal of Medicine.
Kudo M, Ren Z, Guo Y, et al. The Lancet.
Lu S, Yu Y, Zhou J, et al. Translational lung cancer research.
Martling A, Hed Myrberg I, Nilbert M, et al. New England Journal of Medicine.
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. New England Journal of Medicine.
Pramesh CS, Koita R, Sengar M, et al. Bulletin of the World Health Organization.
Janssen QP, van Dam JL, van Bekkum ML, et al. The Lancet Oncology.
Kähler KC, Hassel JC, Ziemer M, et al. Annals of Oncology.
Varshney P, Baghmar S, Sirohi B, et al. Annals of Hepato-Biliary-Pancreatic Surgery.
Wang F, Chen G, Qiu M, et al. Cancer Cell.
Attard G, Agarwal N, Graff JN, et al. Nature Medicine.
Gao B, Carlino MS, Michael M, et al. JAMA Oncology.
Cercek A, Foote MB, Rousseau B, et al. New England Journal of Medicine.
Dalla-Torre H, Gonzalez L, Mendoza-Revilla J, et al. Nature methods.
Ahn DH, Ridinger M, Cannon TL, et al. Journal of Clinical Oncology.
Riess JW, de Langen AJ, Ponce S, et al. JCO Precision Oncology.
Jhaveri KL, Im SA, Saura C, et al. New England Journal of Medicine.
Forde PM, Spicer JD, Provencio M, et al. New England Journal of Medicine.
Wu YL, Wu L, Bi N, et al. Journal of hematology & oncology.
Cardoso F, O'Shaughnessy J, Liu Z, et al. Nature Medicine.
Mittendorf EA, Assaf ZJ, Harbeck N, et al. Nature Medicine.
Cascone T, Bonanno L, Guisier F, et al. Nature Medicine.
Yue D, Wang W, Liu H, et al. The Lancet. Respiratory medicine.
Lentz RW, Lang J, Pitts TM, et al. Cancer research communications.
Yang JC, Wang M, Doucet L, et al. Journal of Clinical Oncology.
Chen W, Fu C, Fang B, et al. Experimental hematology & oncology.
Rao S, Samalin-Scalzi E, Evesque L, et al. The Lancet.
Zhu Y, Solis Soto LM, Pant S, et al. Modern Pathology.
Linder J, Srivastava D, Yuan H, et al. Nature Genetics.
Long GV, Tang H, Desai K, et al. Journal for ImmunoTherapy of Cancer.
Spira AI, Paz-Ares L, Han JY, et al. Journal of Thoracic Oncology.
Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. Journal of Clinical Oncology.
Iwamoto FM, Tanguturi SK, Nayak L, et al. Clinical Cancer Research.
Nakagawa K, Garon EB, Seto T, et al. Journal of Thoracic Oncology.
Ouyang Q, Rodon J, Liang Y, et al. Journal of hematology & oncology.
Makis W, Baghli I, Martinez P. Case Reports in Oncology.
Fasching PA, Stroyakovskiy D, Yardley DA, et al. JAMA Oncology.
Sethna Z, Guasp P, Reiche C, et al. Nature.
Olawaiye AB, Gladieff L, O'Malley DM, et al. The Lancet.
Cortés J, Punie K, Barrios C, et al. New England Journal of Medicine.
Yin Y, Fan Y, Ouyang Q, et al. Nature Medicine.
de Marinis F, Kim TM, Bonanno L, et al. Annals of Oncology.
Lewis S, Hempel T, Jiménez-Luna J, et al. Science.
Hernström V, Josefsson V, Sartor H, et al. The Lancet Digital Health.
Mehr S, Hauke R. Oncology and therapy.
Le X, Kim TM, Loong HH, et al. New England Journal of Medicine.
Hayes T, Rao R, Akin H, et al. Science.
Felip E, Rojas CI, Schenker M, et al. Annals of Oncology.
Jacob JM, Daneshmand S, Necchi A, et al. Journal of Clinical Oncology.
Burstein HJ, Curigliano G, Gnant M, et al. Annals of Oncology.
Agarwal N, Azad AA, Carles J, et al. The Lancet.
Jain H, Karulkar A, Kalra D, et al. Lancet Haematology.
Mountzios G, Sun L, Cho BC, et al. New England Journal of Medicine.
Erices JI, Gonzalez E, Salgado M, et al. Frontiers in Oncology.
Gilene S, Haacker L, Rutan H, Pressey JG. Pediatric Blood & Cancer.
Modi S, Jacot W, Iwata H, et al. Nature Medicine.
Hammel P, Metges JP, Macarulla Mercade T, et al. Journal of Clinical Oncology.
Babiker HM, Picozzi V, Chandana SR, et al. Journal of Clinical Oncology.
Riely GJ, Ahn MJ, Clarke JM, et al. Journal of Thoracic Oncology.
Trapani D, Martins-Branco D, Curigliano G, et al. Annals of Oncology.
Hecht JR, Park YS, Tabernero J, et al. The Lancet.
Piotrowska Z, Passaro A, Nguyen D, et al. Journal of Clinical Oncology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Standard-risk B-cell acute lymphoblastic leukaemia in children
Chronic lymphocytic leukaemia, first treatment
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Localised prostate cancer, intermediate risk
Metastatic triple-negative breast cancer
Cervical cancer
Colorectal cancer
Low-grade serous ovarian cancer
HER2-mutant non-small-cell lung cancer
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Metastatic pheochromocytoma and paraganglioma
Pheochromocytoma and paraganglioma (PPGL). FDA, 14 May 2025, LITESPARK-015 cohort A1; first oral therapy for the disease.
BRAF V600E-mutant colorectal cancer
Cutaneous squamous cell carcinoma. 415 patients randomised after surgery and radiotherapy; 24-month disease-free survival 87.1 against 64.1 per cent, hazard ratio 0.32.
Advanced cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma
Skin cancer (all types). 415 patients randomised after surgery and radiotherapy; 24-month disease-free survival 87.1 against 64.1 per cent with adjuvant cemiplimab.
Neuroendocrine tumours
Lung neuroendocrine tumours (typical and atypical carcinoid)
Small intestinal neuroendocrine tumours
Pancreatic neuroendocrine tumours
Advanced melanoma (unresectable stage III and stage IV)
Mesothelioma
Hepatocellular carcinoma
Advanced hepatocellular carcinoma (BCLC C)
Early-onset colorectal cancer (under 50)
Smouldering multiple myeloma
Small-cell lung cancer
Extensive-stage small-cell lung cancer
Early HER2-positive breast cancer
HER2-positive breast cancer
HER2-positive gastric cancer
Diffuse midline glioma, H3 K27-altered (including DIPG). FDA accelerated approval on 6 August 2025 for progressive H3 K27M-mutant diffuse midline glioma, the first systemic therapy...
Glioma & glioblastoma. 6 August 2025; first systemic therapy for the disease.
Metastatic castration-resistant prostate cancer
Intermediate hepatocellular carcinoma (BCLC B)
KRAS G12C-mutant colorectal cancer
PD-L1-high gastric cancer
Ovarian cancer
Non-small-cell lung cancer
Triple-negative breast cancer (TNBC). ASCENT-03, ASCENT-04, and TROPION-Breast02 all positive; TROPION-Breast02 shows OS benefit.
HER2-positive breast cancer with brain metastases
Early hepatocellular carcinoma (BCLC 0 and A)
HR-positive / HER2-negative breast cancer
Gallbladder cancer. 376 Indian patients (Suryavanshi et al.) and 56 Chilean tumours (Erices et al.) give the high-incidence regions their own frequencies.
Thyroid cancer
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma
Platinum-resistant ovarian cancer
High-risk early HR-positive breast cancer
Multiple myeloma
Relapsed or refractory multiple myeloma
Neuroblastoma (paediatric)
Gastric & gastro-oesophageal junction cancer
Acute myeloid leukaemia. Revumenib NPM1 label (October) and ziftomenib approval (13 November, KOMET-001).
Malignant peripheral nerve sheath tumour (MPNST)
Bladder & urothelial cancer
Mismatch-repair deficient (MSI-high) colorectal cancer
Hypopharyngeal cancer
HPV-positive oropharyngeal cancer
Pancreatic ductal adenocarcinoma. Tumour treating fields with gemcitabine and nab-paclitaxel: 16.2 against 14.2 months in 571 patients with locally advanced disease.
Locally advanced unresectable pancreatic ductal adenocarcinoma
Nasopharyngeal carcinoma
Recurrent and metastatic nasopharyngeal carcinoma
Recurrent or metastatic head and neck squamous cell carcinoma
Chronic lymphocytic leukaemia. BRUIN CLL-321 confirms benefit after covalent BTKi (3 December); next-generation BCL-2 inhibitor reaches patients.
Prostate cancer
Merkel cell carcinoma. Objective response 54.5 per cent in 101 chemotherapy-naive patients, median progression-free survival 16.0 months and 63 per cent alive at three years.
Metastatic and recurrent anal squamous cell carcinoma
Pancreatic ductal adenocarcinoma. Neoadjuvant FOLFIRINOX 21.9 versus 21.3 months against gemcitabine chemoradiotherapy.
Melanoma
Acute lymphoblastic leukaemia. FDA lifts REMS for approved CAR-T products; ziftomenib and revumenib studied in KMT2Ar ALL.
Endometrial cancer
Platinum-resistant ovarian cancer
Gastric & gastro-oesophageal junction cancer
HR-positive metastatic breast cancer after CDK4/6 inhibitors
Diffuse large B-cell lymphoma
EGFR-mutated non-small-cell lung cancer
ROS1-positive non-small-cell lung cancer
MET exon 14 and MET-amplified non-small-cell lung cancer
Breast cancer (all types). Axillary surgery omitted in 4,858 patients, regional nodal irradiation dropped after a complete nodal response, and no survival gain from chest-wall radi...
Oesophageal cancer
Lung cancer (all types). From 1 January 2025 lung cancer is staged by the ninth edition: the T descriptors unchanged, N2 split into N2a and N2b by the number of mediastinal station...
Biliary tract cancer (cholangiocarcinoma)
Gallbladder cancer. 36-month survival 14.6 vs 6.9 percent with durvalumab. Residual disease hazard ratios of 26 (2025) and 15.86 (2026) in two cohorts.
Polycythaemia vera (PV). Rusfertide added to standard care made most patients phlebotomy-free over weeks 20 to 32.
Tenosynovial giant cell tumour (TGCT). FDA approval 14 February 2025 for symptomatic TGCT where surgery would worsen function.
Sarcomas (soft tissue, bone, GIST)
NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
San Francisco, CA
The funding rounds on company records, each with the source that states the figure.
$115m. Series C announced in late 2025 as stated in the July 2026 release
$5m. Total sold of a 12 million US dollar offering per Form D filed February 2025; issuer address given as Eindhoven
$132m. Endpoints reports a USD 132 million raise in July 2025; the Series B label comes from the PR Newswire headline seen in search results, not from a fetched page
$20m. Led by AIX Ventures, March 2025.
$9.1bn. 129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer comp...
$382m. Nasdaq listing via merger with Helix Acquisition Corp. II on 11 August 2025; about 261 million US dollar PIPE led by Cormorant plus about 120 million from the trust, roughly...
$187m
$2.1bn. AbbVie paid cash consideration of $2.1 billion ($1.9 billion net of cash acquired); completed August 2025
$4.379 in cash per share plus a contingent value right; tender offer completed 18 August 2025
$44m. First close, August 2025; led by EQT Life Sciences with co-leads Advent Life Sciences and British Business Bank.
Acquired by Tempus AI on 11 March 2025; Deep 6 specific consideration not broken out in the 10-Q
$250m. USD 250 million upfront plus up to USD 752.5 million in milestones; all-cash, announced 28 January 2025
$3.0bn. 3.05 billion US dollars in cash; completion announced 29 December 2025
$1.247 in cash per share plus a contingent value right; agreement 1 July 2025, merger completed 14 August 2025
$23m. Led by Larry Ellison with Aguras Pathology Investments, July 2025; total funding $45 million. Source is the company release distributed via Newswire.com.
$51m. Amount sold at filing of a $51.6 million offering, first sale 24 September 2025
$3m. EUR 2.5 million EIC Transition Programme grant, reported by the company as USD 2.8 million
KOSDAQ listing, 2,500,000 shares at KRW 20,000, gross proceeds about KRW 50 billion; trading from 14 February 2025 under code 475830
$100m. Post-IPO convertible preferred stock investment of KRW 145 billion (approximately USD 100 million) led by KB Investment; the company does not use a series letter
$21m. Round not named by the company; labelled Series B here because it followed the 2021 Series A. Led by Salica Investments; total raised to date USD 38 million
$49m. ARPA-H POSEIDON award of up to $49.1 million for at-home multi-cancer early detection tests, October 2025.
$27m. First close of about $27 million (approximately GBP 22 million) led by Ventura Capital, January 2025.
$365m. Post-money valuation about $1.6 billion, May 2025; investors not named in the release.
$60m. Total sold per Form D filed August 2025; first sale July 2025
$1.5bn. $9.00 per share in cash (about $1.0 billion equity value) plus a contingent value right of up to $4.00 per share, total deal value up to about $1.5 billion; announced 26 No...
Lilly's Q1 2025 results attribute most of a 1.57 billion US dollar acquired in-process R&D charge to the acquisition of Scorpion's PI3K-alpha inhibitor programme STX-478; headline...
$153m
$97m. Brought total raised to USD 275 million
Public follow-on fundraising of about EUR 105 million (private placement plus PrimaryBid retail offering at EUR 1.02 per share), plus a EUR 39.3 million reserved capital increase f...
$200m. Total sold of a 250 million US dollar offering per Form D filed September 2025
$10m. Co-led by NEXT Ventures and SemperVirens; total raised USD 17.6 million
$120m. Oversubscribed; co-led by Ascenta Capital and Bessemer Venture Partners; closed December 2025
$0.34 in cash per share plus a contingent value right; agreement 27 June 2025, merger completed 11 August 2025
$19m. Equity offering of up to USD 31.96 million, first sale 7 October 2025, USD 18.67 million sold at filing
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Crit Care Med
The Lancet Oncology
Cancers
npj Precision Oncology
Gynecologic Oncology
Medical Sciences
J Clin Med
New England Journal of Medicine
NEJM
Revue Médicale Suisse
BMJ Oncology
The Lancet Public Health
New England Journal of Medicine
JCO
Clin Pharmacol Ther
Archives of Disease in Childhood
Journal of Thoracic Oncology
JMIR Cancer
Journal of Clinical Oncology
JCO
The Lancet Regional Health - Europe
The Lancet
International Journal of Gynecological Cancer
NEJM
NEJM
Lancet Oncology
BMJ Open
Critical Reviews in Oncology/Hematology
Seminars in Oncology
Clinical Cancer Research
Nature Communications
Cancers
Future Oncology
NEJM
Journal of Clinical Neuroscience
Lancet
New England Journal of Medicine
Journal of the National Comprehensive Cancer Network
JCO
NEJM
Nature Cancer
Endocrine-Related Cancer
Blood Advances
JCO
Cancer
Cell Death & Differentiation
NEJM
BMC Cancer
Lancet Haematology
Annual Review of Pharmacology and Toxicology
Journal of Thoracic Oncology
The Lancet Oncology
Annals of Oncology
NEJM
NEJM
Journal of Thoracic Oncology
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Actual primary completion date on ClinicalTrials.gov.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Actual primary completion date on ClinicalTrials.gov.
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.